Martin Shkreli, 32, founder and chief executive of Turing
Pharmaceuticals, purchased the rights to Daraprim which is used for
treating life-threatening parasitic infections - for $55million. He
raised the price of the drug from $13.50 per tablet to $750 per tablet.
Since the announcement, people across social media have criticized the
price increase, but Shkreli has backed the decision, saying that his
company 'need to turn a profit on the drug'.
Comments
Sick. What goes around comes around.